Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis
Our study implies that albendazole can act as a potent agonist of LRRN3 during fibroblast to myofibroblast differentiation and its oral administration shows potential as a viable therapeutic approach for managing IPF.
Authors
- Jun Yu (ORCID: https://orcid.org/0000-0002-3390-5901)
- Chenxi Zeng (ORCID: https://orcid.org/0000-0001-7189-8637)
- Huilan Zhang (ORCID: https://orcid.org/0000-0002-2366-7321)
- Huihui Yue (ORCID: https://orcid.org/0000-0002-6719-2268)
- Congjian Wang (ORCID: https://orcid.org/0000-0002-0778-9927)
- Tianlai Wang (ORCID: https://orcid.org/0009-0004-5836-7750)
- Xiangning Fu (ORCID: https://orcid.org/0000-0003-4670-1438)
- Qing Zhou (ORCID: https://orcid.org/0000-0003-4508-9224)
- Xuetao Ju
- Long He (ORCID: https://orcid.org/0000-0002-2814-6541)
- Yi Wang (ORCID: https://orcid.org/0000-0001-9081-120X)
Institutions
- Tongji University (CN)
- Shanghai East Hospital (CN)
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1186/s12967-024-05655-0
- Citations
- 13
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 5.45
Funders
- National Natural Science Foundation of China
- Huazhong University of Science and Technology
- Tongji University